Francisco Robert- Vizcarrondo MD
Chief, Hematology/Oncology Birmingham VA Hospital
Join to view full profile
2000 6th Ave SBirmingham, AL 35233
Phone+1 205-934-9999
Join Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 1 invite waiting! - Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Francisco Vizcarrondo, MD is an oncologist in Birmingham, Alabama. He is currently licensed to practice medicine in Alabama. He is a Chief at Hematology/Oncology Birmingham VA Hospital.
Education & Training
University of Puerto RicoFellowship, Hematology and Medical Oncology, 1974 - 1976- University of Puerto Rico School of MedicineClass of 1969
Certifications & Licensure
AL State Medical License 1974 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification MyHealth@UABMedicine, UAB Health System, 2012, 2014-2017
- CMS Meaningful Use Stage 1 Certification Powerchart and Cerner Healthe, Cerner Corporation, 2012, 2014-2017
- CMS Meaningful Use Stage 2 Certification PowerChart (CQM), Cerner Corporation, 2012, 2014-2017
Publications & Presentations
PubMed
- 36 citationsFirst-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid Tumors.Khanh T. Do, Laura Q.M. Chow, Karen L. Reckamp, Rachel E. Sanborn, Howard A. Burris
The Oncologist. 2021-11-01 - 24 citationsVeliparib and nivolumab in combination with platinum doublet chemotherapy in patients with metastatic or advanced non-small cell lung cancer: A phase 1 dose escalation...Jeffrey M. Clarke, Jyoti D. Patel, Francisco Robert, Ebenezer A. Kio, Eddie Thara
Lung Cancer. 2021-09-17 - 9 citationsSWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study)Hossein Borghaei, Mary W. Redman, Karen Kelly, Saima N. Waqar, Francisco Robert
Clinical Lung Cancer. 2021-05-01
